Search Technologies

Testing for biological activity of glucocorticoids and many other steroid endocrine-disrupting chemicals (EDCs) has not been previously performed. An automated, highly reproducible, and low cost assay detects biologically active steroidal EDCs and is suitable for wide application in testing water samples. The National Cancer Institute seeks partners for collaborative co-development research and/or licensing to move this technology into the public domain.

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the development and commercialization of a diagnostic assay that detects sequence-specific (viral) RNA.

Researchers at the National Cancer Institute (NCI) seek licensing and/or co-development research collaborations for a new class of conformationally restricted cyanine dyes

The National Cancer Institute (NCI) seeks research co-development or licensees for a precision medicine approach that classifies patients’ DLBCL into genetic subtypes that are predictive of treatment response.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of diffusion tensor distribution imaging (DTD-MRI) in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications.

This technology consists of highly specific rabbit monoclonal antibodies reactive with phosphorylated tyrosine located at amino acid 1235 in the human MET sequence. Binding to this pYl235 residue is independent of the phosphorylation of other tyrosines in the vicinity (1230 and 1234), does not cross-react with these nearby phosphotyrosine residues, and does not occur when Y1235 is unphosphorylated. Researchers at the NCI seek licensing and/or co-development research collaborations  to commercialize and develop a companion diagnostic for selective MET inhibitors.

The National Cancer Institute seeks licensees and/or co-development partners for methods that provide significant improvements in examining clinically relevant tissue samples, by improving spatial resolution and tissue depth using optical trapping. 

NCI Researchers have discovered Interferon-lambda 4 (IFNL4), a protein found through analysis of genomic data. Preliminary studies indicate that this protein may play a role in the clearance of HCV and may be a new target for diagnosing and treating HCV infection. The National Cancer Institute (NCI) Division of Cancer Epidemiology and Genetics (DCEG) Immunoepidemiology Branch is seeking statements of capability or interest from parties interested in in-licensing or collaborative research to further co-develop a gene-based diagnostic for Hepatitis C virus (HepC, HCV).

The National Cancer Institute Laboratory of Molecular Biology seeks parties to license or co-develop and commercialize antibody drug/toxin conjugates as liver cancer therapy and diagnostics.